Compare Philip Morris International Inc. (PM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: Philip Morris International Inc. pays a 3.13% dividend while State Street SPDR S&P Biotech ETF pays none, and Philip Morris International Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| PM | XBI | |
|---|---|---|
Market Cap | $293.07B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $192.98 | $164.28 |
52-Week Low | $144.33 | $85.16 |
Enterprise Value | $339.57B | — |
Dividend Yield | 3.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $194.30, up 0.82% today, with strong analyst support (68% buy ratings) and a consensus price target of $194. The stock shows bullish technical momentum above key support levels, supported by robust fundamentals including 2025 revenue of $40.65B and net income of $11.35B. Recent news highlights include a $500M impairment charge and updated 2026 guidance, while the IQOS brand gained recognition as a top global brand.
PM offers stable dividend income and growth potential, but faces headwinds from cost pressures, currency volatility, and regulatory risks in tobacco markets. The current valuation at 26.47 P/E appears reasonable given earnings consistency, though investors should monitor margin trends and illicit market impacts in Europe. Near-term price action hinges on Q2 2026 earnings versus the $2.04 EPS estimate.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
